Mandibular stabilization splint

PreclinicalSmall molecule

Mandibular stabilization splint is one of 4 small molecule programs targeting Temporomandibular Disorders. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Temporomandibular DisordersRecruiting

Temporomandibular DisordersPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Temporomandibular Disorders

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Kytril

CConrado Roberto Hoffmann Filho

Approved

1 3

Cyclobenzaprine Hydrochloride

NNeurana Pharmaceuticals, Inc.

Preclinical

1 4

Mandibular stabilization splint

CCairo University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Temporomandibular Disorders1 trial

Mandibular Splint vs Botox Injection in Lateral Pterygoid on Cervical Muscle Activity in Patients With Temporomandibular Disorders

Recruiting·—·N/A·NCT06553950·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mandibular stabilization splint. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mandibular stabilization splint compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mandibular stabilization splint. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cairo University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCairo University

Mandibular stabilization splint

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Temporomandibular Disorders1 trial

References

Drug Info

Quick Facts

Related News